JP2021514618A5 - - Google Patents
Info
- Publication number
- JP2021514618A5 JP2021514618A5 JP2020543995A JP2020543995A JP2021514618A5 JP 2021514618 A5 JP2021514618 A5 JP 2021514618A5 JP 2020543995 A JP2020543995 A JP 2020543995A JP 2020543995 A JP2020543995 A JP 2020543995A JP 2021514618 A5 JP2021514618 A5 JP 2021514618A5
- Authority
- JP
- Japan
- Prior art keywords
- igm
- antibody
- variant
- amino acid
- constant region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023183845A JP2024016093A (ja) | 2018-03-01 | 2023-10-26 | ＩｇＭ血清半減期に影響を及ぼすＩｇＭ Ｆｃ及びＪ鎖の変異 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637186P | 2018-03-01 | 2018-03-01 | |
| US62/637,186 | 2018-03-01 | ||
| PCT/US2019/020374 WO2019169314A1 (en) | 2018-03-01 | 2019-03-01 | IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023183845A Division JP2024016093A (ja) | 2018-03-01 | 2023-10-26 | ＩｇＭ血清半減期に影響を及ぼすＩｇＭ Ｆｃ及びＪ鎖の変異 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021514618A JP2021514618A (ja) | 2021-06-17 |
| JP2021514618A5 true JP2021514618A5 (enExample) | 2022-03-07 |
| JP7376490B2 JP7376490B2 (ja) | 2023-11-08 |
Family
ID=67805543
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543995A Active JP7376490B2 (ja) | 2018-03-01 | 2019-03-01 | ＩｇＭ血清半減期に影響を及ぼすＩｇＭ Ｆｃ及びＪ鎖の変異 |
| JP2023183845A Pending JP2024016093A (ja) | 2018-03-01 | 2023-10-26 | ＩｇＭ血清半減期に影響を及ぼすＩｇＭ Ｆｃ及びＪ鎖の変異 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023183845A Pending JP2024016093A (ja) | 2018-03-01 | 2023-10-26 | ＩｇＭ血清半減期に影響を及ぼすＩｇＭ Ｆｃ及びＪ鎖の変異 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10899835B2 (enExample) |
| EP (1) | EP3758752A4 (enExample) |
| JP (2) | JP7376490B2 (enExample) |
| KR (1) | KR102745232B1 (enExample) |
| CN (1) | CN111787951B (enExample) |
| AU (2) | AU2019227984A1 (enExample) |
| BR (1) | BR112020017296A2 (enExample) |
| IL (1) | IL276590A (enExample) |
| MX (1) | MX2020009069A (enExample) |
| SG (1) | SG11202008343YA (enExample) |
| WO (1) | WO2019169314A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015120474A1 (en) | 2014-02-10 | 2015-08-13 | Igm Biosciences, Inc. | Iga multi-specific binding molecules |
| EP4011910A1 (en) | 2014-04-03 | 2022-06-15 | IGM Biosciences, Inc. | Modified j-chain |
| PT3247728T (pt) | 2015-01-20 | 2020-07-16 | Igm Biosciences Inc | Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas |
| KR102357312B1 (ko) | 2015-03-04 | 2022-02-03 | 아이쥐엠 바이오사이언스 인코포레이티드 | Ｃｄ20 결합 분자 및 그의 용도 |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| AU2016249404B2 (en) | 2015-04-17 | 2021-01-21 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| PT3355913T (pt) | 2015-09-30 | 2024-12-18 | Igm Biosciences Inc | Moléculas de ligação com cadeia j modificada |
| ES2819870T3 (es) | 2015-09-30 | 2021-04-19 | Igm Biosciences Inc | Moléculas de unión con cadena J modificada |
| WO2017196867A1 (en) | 2016-05-09 | 2017-11-16 | Igm Biosciences, Inc. | Anti-pd-l1 antibodies |
| CA3055790A1 (en) | 2017-04-07 | 2018-10-11 | Igm Biosciences, Inc. | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function |
| CN111787951B (zh) | 2018-03-01 | 2025-06-17 | Igm生物科学股份有限公司 | 影响IgM血清半衰期的IgM Fc和J链突变 |
| JP2022544405A (ja) | 2019-08-15 | 2022-10-18 | アイジーエム バイオサイエンシズ インコーポレイテッド | 免疫刺激性多量体型結合分子 |
| JP7585305B2 (ja) * | 2019-08-17 | 2024-11-18 | アイジーエム バイオサイエンシズ インコーポレイテッド | 多量体の二重特異性抗ｃｄ１２３結合分子及びその使用 |
| CA3151237A1 (en) * | 2019-09-19 | 2021-03-25 | Ramesh Baliga | Multimeric antibodies with enhanced selectivity for cells with high target density |
| CN110669134A (zh) * | 2019-10-15 | 2020-01-10 | 广东菲鹏生物有限公司 | IgM-FC片段、IgM-FC抗体及制备方法和应用 |
| BR112022013071A2 (pt) * | 2020-01-06 | 2022-09-20 | Igm Biosciences Inc | Moléculas de ligação multiméricas altamente sialiladas |
| JP7729833B2 (ja) * | 2020-03-23 | 2025-08-26 | サイトアーム カンパニー リミテッド | 武装免疫細胞を産生する際に使用するための二重特異性抗体 |
| JP2023522962A (ja) | 2020-04-22 | 2023-06-01 | アイジーエム バイオサイエンシズ インコーポレイテッド | Ｐｄ－１アゴニスト多量体結合分子 |
| MX2022014259A (es) * | 2020-05-12 | 2022-12-07 | Igm Biosciences Inc | Uso de una molecula de union anti-dr5 multimerica en combinacion con una terapia contra el cancer para tratar el cancer. |
| US20220033851A1 (en) * | 2020-08-03 | 2022-02-03 | Roger B. Swartz | mRNA, episomal and genomic integrated lentiviral and gammaretroviral vector expression of dimeric immunoglobulin A and polymeric immunoglobulin A to Enable Mucosal and Hematological Based Immunity/Protection via Gene Therapy for Allergens, viruses, HIV, bacteria, pneumonia, infections, pathology associated proteins, systemic pathologies, cancer, toxins and unnatural viruses. CAR engineered and non-CAR engineered immune cell expression of dimeric immunoglobulin A and polymeric immunoglobulin A. |
| KR102450007B1 (ko) * | 2020-10-16 | 2022-10-04 | 주식회사 아이엠바이오로직스 | IgM 영역을 이용한 융합단백질 플랫폼 |
| EP4294829A4 (en) * | 2021-02-17 | 2025-03-19 | IGM Biosciences Inc. | ANTI-CD123 BINDING MOLECULES AND THEIR USES |
| WO2023036305A1 (zh) | 2021-09-13 | 2023-03-16 | 沈阳眼产业技术研究院有限公司 | 抗periostin人源化单克隆抗体及其制备方法与应用 |
| WO2023064766A1 (en) * | 2021-10-11 | 2023-04-20 | Igm Biosciences, Inc. | Lateral flow device and uses thereof |
| CA3245061A1 (en) | 2022-04-07 | 2023-10-12 | Repertoire Immune Medicines, Inc. | T-CELL RECEIVER MULTIMERS AND THEIR USES |
| CN118369336A (zh) * | 2022-04-15 | 2024-07-19 | Im生技股份有限公司 | 具有改进半衰期的融合蛋白平台 |
| US20240025996A1 (en) * | 2022-07-11 | 2024-01-25 | Fred Hutchinson Cancer Center | Igm-multimerized single-domain antibodies that bind ror1 |
| CN121405820B (zh) * | 2025-12-29 | 2026-06-26 | 江苏谱新生物医药有限公司 | 一种病毒包膜嵌合受体及其相关生物材料和应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2249195A1 (en) * | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US6045774A (en) * | 1997-01-10 | 2000-04-04 | Epicyte Pharmaceutical Inc. | J chain polypeptide targeting molecule linked to an imaging agent |
| AU740918B2 (en) * | 1997-01-10 | 2001-11-15 | Plantibodies Corporation | Novel epithelial tissue targeting agent |
| US20050129616A1 (en) | 2001-05-25 | 2005-06-16 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| US7601351B1 (en) | 2002-06-26 | 2009-10-13 | Human Genome Sciences, Inc. | Antibodies against protective antigen |
| US20040248299A1 (en) | 2002-12-27 | 2004-12-09 | Sumedha Jayasena | RNA interference |
| US20050014932A1 (en) | 2003-05-15 | 2005-01-20 | Iogenetics, Llc | Targeted biocides |
| AU2005304973A1 (en) | 2004-11-05 | 2006-05-18 | Palingen, Inc. | Antibody induced cell membrane wounding |
| EP1888649A2 (en) * | 2005-05-09 | 2008-02-20 | GlycArt Biotechnology AG | Antigen binding molecules having modified fc regions and altered binding to fc receptors |
| WO2010008690A1 (en) | 2008-07-14 | 2010-01-21 | Uchicago Argonne, Llc | Methods for systematic control of protein stability |
| MX2012004029A (es) * | 2009-10-07 | 2012-05-08 | Macrogenics Inc | Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso. |
| WO2013120012A2 (en) | 2012-02-08 | 2013-08-15 | Igm Biosciences Inc. | Cdim binding proteins and uses thereof |
| EP4292657A3 (en) | 2013-03-15 | 2024-03-20 | Dana Farber Cancer Institute, Inc. | Flavivirus neutralizing antibodies and methods of use thereof |
| CN105722855B (zh) | 2013-09-05 | 2021-04-23 | Igm生物科学股份有限公司 | 恒定链经修饰的双特异性五价和六价Ig-M抗体 |
| WO2015120474A1 (en) | 2014-02-10 | 2015-08-13 | Igm Biosciences, Inc. | Iga multi-specific binding molecules |
| EP4011910A1 (en) | 2014-04-03 | 2022-06-15 | IGM Biosciences, Inc. | Modified j-chain |
| PT3247728T (pt) | 2015-01-20 | 2020-07-16 | Igm Biosciences Inc | Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas |
| KR102357312B1 (ko) | 2015-03-04 | 2022-02-03 | 아이쥐엠 바이오사이언스 인코포레이티드 | Ｃｄ20 결합 분자 및 그의 용도 |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| AU2016249404B2 (en) | 2015-04-17 | 2021-01-21 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| JP6860270B2 (ja) * | 2015-07-09 | 2021-04-14 | ディスペンシング・テクノロジーズ・ベスローテン・フェンノートシャップＤｉｓｐｅｎｓｉｎｇ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｂ．Ｖ． | 流体を定量供給するためのシステムおよび該流体供給システムを製造する方法 |
| PT3355913T (pt) | 2015-09-30 | 2024-12-18 | Igm Biosciences Inc | Moléculas de ligação com cadeia j modificada |
| ES2819870T3 (es) | 2015-09-30 | 2021-04-19 | Igm Biosciences Inc | Moléculas de unión con cadena J modificada |
| WO2017196867A1 (en) | 2016-05-09 | 2017-11-16 | Igm Biosciences, Inc. | Anti-pd-l1 antibodies |
| AU2017299608A1 (en) | 2016-07-20 | 2019-02-07 | Igm Biosciences, Inc. | Multimeric CD137/4-1BB binding molecules and uses thereof |
| US20190330374A1 (en) | 2016-07-20 | 2019-10-31 | Igm Biosciences, Inc. | Multimeric ox40 binding molecules and uses thereof |
| US20190338041A1 (en) | 2016-07-20 | 2019-11-07 | Igm Biosciences, Inc. | Multimeric cd40 binding molecules and uses thereof |
| CA3030659A1 (en) | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric gitr binding molecules and uses thereof |
| CA3055790A1 (en) | 2017-04-07 | 2018-10-11 | Igm Biosciences, Inc. | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function |
| EP3759229A4 (en) | 2018-02-26 | 2021-12-29 | IGM Biosciences Inc. | Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer |
| CN111787951B (zh) | 2018-03-01 | 2025-06-17 | Igm生物科学股份有限公司 | 影响IgM血清半衰期的IgM Fc和J链突变 |
| AU2019368289A1 (en) | 2018-10-23 | 2021-04-29 | Igm Biosciences, Inc. | Multivalent IgM- and IgA-Fc-based binding molecules |
| US20220106398A1 (en) | 2019-02-08 | 2022-04-07 | Igm Biosciences, Inc. | Anti-gitr antigen-binding domains and uses thereof |
| JP2022544405A (ja) | 2019-08-15 | 2022-10-18 | アイジーエム バイオサイエンシズ インコーポレイテッド | 免疫刺激性多量体型結合分子 |
| JP7585305B2 (ja) | 2019-08-17 | 2024-11-18 | アイジーエム バイオサイエンシズ インコーポレイテッド | 多量体の二重特異性抗ｃｄ１２３結合分子及びその使用 |
| MX2022002239A (es) | 2019-08-23 | 2022-03-22 | Igm Biosciences Inc | Glicovariantes de igm. |
| CA3151237A1 (en) | 2019-09-19 | 2021-03-25 | Ramesh Baliga | Multimeric antibodies with enhanced selectivity for cells with high target density |
| BR112022013071A2 (pt) | 2020-01-06 | 2022-09-20 | Igm Biosciences Inc | Moléculas de ligação multiméricas altamente sialiladas |
| JP2023522962A (ja) | 2020-04-22 | 2023-06-01 | アイジーエム バイオサイエンシズ インコーポレイテッド | Ｐｄ－１アゴニスト多量体結合分子 |
| MX2022014259A (es) | 2020-05-12 | 2022-12-07 | Igm Biosciences Inc | Uso de una molecula de union anti-dr5 multimerica en combinacion con una terapia contra el cancer para tratar el cancer. |
| US20230058162A1 (en) | 2020-07-27 | 2023-02-23 | Igm Biosciences, Inc. | Multimeric coronavirus binding molecules and uses thereof |
| WO2022109023A1 (en) | 2020-11-17 | 2022-05-27 | Igm Biosciences, Inc. | Uses of effector cell engaging molecules with moieties of differing potencies |
| EP4294829A4 (en) | 2021-02-17 | 2025-03-19 | IGM Biosciences Inc. | ANTI-CD123 BINDING MOLECULES AND THEIR USES |
| US20220267415A1 (en) | 2021-02-17 | 2022-08-25 | The Board Of Regents Of The University Of Texas System | Multimeric sars-cov-2 binding molecules and uses thereof |
| WO2023064766A1 (en) | 2021-10-11 | 2023-04-20 | Igm Biosciences, Inc. | Lateral flow device and uses thereof |
| WO2023064900A1 (en) | 2021-10-15 | 2023-04-20 | Igm Biosciences, Inc. | Methods of use of multimeric anti-pd-l1 binding molecules |
| JP2025506341A (ja) | 2022-02-03 | 2025-03-11 | アイジーエム バイオサイエンシズ インコーポレイテッド | 抗ｃｄ３８結合分子及びその使用 |
| WO2023178253A2 (en) | 2022-03-18 | 2023-09-21 | Igm Biosciences, Inc. | Use of a multimeric anti-pd-l1 binding molecule in combination with a monoclonal antibody therapy |
| WO2024073700A2 (en) | 2022-09-30 | 2024-04-04 | Igm Biosciences, Inc. | Methods of treating autoimmune disorders using multimeric anti-cd20/anti-cd3 antibodies |
| WO2024138072A1 (en) | 2022-12-22 | 2024-06-27 | Igm Biosciences, Inc. | Methods of treating autoimmune disorders using multimeric anti-cd38/anti-cd3 antibodies |
| WO2024148339A1 (en) | 2023-01-06 | 2024-07-11 | Igm Biosciences, Inc. | Use of a multimeric anti-dr5 antibody for treating cancer |
| JP2026502759A (ja) | 2023-01-06 | 2026-01-27 | アイジーエム バイオサイエンシズ インコーポレイテッド | Ｔ細胞共刺激多量体結合分子及びその使用 |
| WO2024229151A2 (en) | 2023-05-02 | 2024-11-07 | Igm Biosciences, Inc. | Multimeric coronavirus binding molecules and uses thereof |
-
2019
- 2019-03-01 CN CN201980016388.5A patent/CN111787951B/zh active Active
- 2019-03-01 KR KR1020207023441A patent/KR102745232B1/ko active Active
- 2019-03-01 MX MX2020009069A patent/MX2020009069A/es unknown
- 2019-03-01 WO PCT/US2019/020374 patent/WO2019169314A1/en not_active Ceased
- 2019-03-01 AU AU2019227984A patent/AU2019227984A1/en not_active Abandoned
- 2019-03-01 EP EP19760662.7A patent/EP3758752A4/en active Pending
- 2019-03-01 JP JP2020543995A patent/JP7376490B2/ja active Active
- 2019-03-01 SG SG11202008343YA patent/SG11202008343YA/en unknown
- 2019-03-01 BR BR112020017296-0A patent/BR112020017296A2/pt active Search and Examination
-
2020
- 2020-03-23 US US16/827,100 patent/US10899835B2/en active Active
- 2020-08-09 IL IL276590A patent/IL276590A/en unknown
- 2020-12-03 US US17/110,550 patent/US20210087273A1/en not_active Abandoned
-
2023
- 2023-10-26 JP JP2023183845A patent/JP2024016093A/ja active Pending
- 2023-12-29 US US18/400,974 patent/US12649791B2/en active Active
-
2025
- 2025-11-21 AU AU2025271120A patent/AU2025271120A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7662516B2 (ja) | Ｐｄ－１標的化ｉｌ－１５／ｉｌ－１５ｒアルファｆｃ融合タンパク質およびその組み合わせ療法での使用 | |
| JP2020517287A5 (enExample) | ||
| JP7209464B2 (ja) | ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体 | |
| JP2020500510A5 (enExample) | ||
| JP2021159081A5 (enExample) | ||
| CN106029694A (zh) | 治疗性肽 | |
| JP2018517431A5 (enExample) | ||
| JP2016536322A5 (enExample) | ||
| JP2017504578A5 (enExample) | ||
| EP3221357A1 (en) | Common light chains and methods of use | |
| RU2017108203A (ru) | Слитые белки sirp-альфа с иммуноглобулином | |
| JP2017509335A5 (enExample) | ||
| RU2018128215A (ru) | Антитела против mica | |
| JP2020519293A5 (enExample) | ||
| JP2023525495A (ja) | 抗ｃｄ２６タンパク質及びそれらの使用法 | |
| JP2011526249A5 (enExample) | ||
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| CN116925215A (zh) | 抗血清白蛋白纳米抗体及其衍生物 | |
| JP2017509323A5 (enExample) | ||
| EP3337825A1 (en) | Antibody or antibody fragment or non-ig scaffold binding to a binding region of an anti-n-methyl-d-aspartate (nmda) receptor antibody | |
| JP2026004299A5 (enExample) | ||
| US20250206820A1 (en) | Ilt3 and cd3 binding agents and methods of use thereof | |
| WO2022056197A1 (en) | Immune targeting molecules and uses thereof | |
| CN117120478A (zh) | 一种抗原结合分子 | |
| WO2019199916A1 (en) | Fab-based trispecific antibodies |